EIF2A and prostate carcinoma: Previous studies indicate that activated PERK-eIF2α signaling could drive the expression of GDF15 [38], which is discovered as an important mediator in promoting cell growth of prostate cancer [42] and EMT of CRC cells in vitro [43], and even acts as a driver in cachexia progression [44, 45].